10% 医药生物 沪深300 10% 医药生物 沪深300 超配（维持） 医药生物行业双周报（2025/7/11-2025/7/24） 第十一批集采工作持续推进 -35% -30% -25% -20% -15% -35% -30% -35% -30% -25% -20% -40% -20% 0% 20% 22-03 22-05 22-07 22-09 22-11 23-01 23-03 医药生物 沪深300 -30% -25% -20% -15% -10% -5% 0% 5% 10% 医药生物 沪深300 2025 年 7 月 25 日 分析师：谢雄雄 SAC 执业证书编号： S0340523110002 电话：0769-22110925 邮箱： xiexiongxiong@dgzq.com.cn 医药生物（申万）指数走势 资料来源：iFind，东莞证券研究所 相关报告 ◼ SW医药生物行业跑赢同期沪深300指数。2025年7月11日-2025年7月24 日，SW医药生物行业上涨7.84%，跑赢同期沪深300指数约4.13个百分点。 SW医药生物行业三级细分板块中，多数细分板块均录得正收益，其中医 疗研发外包 ...

内容概要：胸腔镜是一种利用高清摄像和显示技术，通过微小切口进入胸腔进行直观观察和操作的现代 医疗设备，是医用内窥镜的一种。胸腔镜主要用于胸腔疾病的诊断和治疗，包括肺部疾病诊疗、纵隔疾 病诊疗、胸膜疾病诊疗。由于肺癌、慢性阻塞性肺病 (COPD)和胸腔积液等呼吸系统疾病发病率不断上 升，医学胸腔镜作为一种微创手术技术，其需求大幅增长。叠加居民健康意识日益提升及胸腔镜技术不 断进步，胸腔镜迎来更广阔的发展空间。数据显示，2024年全球胸腔镜市场规模约为22.2亿美元，同比 增长4.2%。未来胸腔镜市场规模将保持增长态势，预计到2031年市场规模将达31亿美元。中国市场， 随着人们对胸膜疾病认知的提高以及对精准诊断工具需求的增长，胸腔镜市场需求明显增加。从招投标 情况来看，据统计，2024年全国胸腔镜公开中标事件共计404次，中标金额5.09亿元，涉及设备销售685 台/套/批，采购均价为74.31万元/台（套）。我国在胸腔镜领域起步较晚，长期以来，我国胸腔镜市场 被外资企业如卡尔史托斯、奥林巴斯等巨头牢牢占据。但近年来，随着国内企业研发及制造能力不断提 升，迈瑞、欧谱曼迪、康基等本土企业竞争力与影响力明显增强，市 ...

Investment Rating - Industry investment rating: Stronger than the market (maintained) [1][23] Core Viewpoints - The demand for medical equipment bidding continues to be strong, with a significant recovery in procurement activities expected to improve company financial performance [3][5] - The overall market size for medical device bidding in China exceeded 80 billion yuan in the first half of 2025, showing a year-on-year growth of over 60% [3][11] - Major provinces driving the procurement include Liaoning, Hainan, Ningxia, Fujian, and Shanxi, with imaging equipment being the core focus of upgrades [3][5] Summary by Sections Market Trends - The procurement scale for medical devices has remained high since 2025, with June procurement figures showing significant year-on-year increases across various categories, such as ultrasound (1.391 billion yuan, +49%), CT (1.938 billion yuan, +59%), and MRI (1.531 billion yuan, +64%) [4][12][15] - The bidding recovery is evident, with monthly procurement figures for 2025 showing consistent growth, despite a slight slowdown in June [3][11] Company Performance - Leading companies are expected to benefit significantly from the recovery in equipment bidding, with firms like Mindray Medical projecting a noticeable recovery in overall performance starting from Q3 2025 [3][5][21] - In June 2025, the bidding amounts for major domestic companies were as follows: Mindray (623 million yuan, +15%), United Imaging (769 million yuan, +35%), and Kaili Medical (102 million yuan, +73%) [4][18] Investment Recommendations - The report suggests focusing on domestic leading enterprises that are enhancing their high-end and intelligent medical equipment layouts, such as Mindray Medical, United Imaging, Kaili Medical, and Aohua Endoscopy [5][21] - The continuous support for equipment updates from government policies is expected to positively impact the industry, with a projected increase in procurement activities [21]

Investment Rating - The industry investment rating is "Outperform the Market" [2][45] Core Insights - The total bidding amount for medical devices in June 2025 reached 12.618 billion yuan, representing a year-on-year growth of 30% and a total of 83.817 billion yuan for the first half of 2025, with an overall year-on-year increase of 64% [3][9][10] Summary by Sections Medical Device Bidding Overview - The medical device bidding amount in June 2025 was 12.618 billion yuan, showing a year-on-year increase of 30% and a quarter-on-quarter decrease of 6% [9] - The cumulative bidding amount for the first half of 2025 was 83.817 billion yuan, with a year-on-year growth of 64% [10] Domestic Brands - Mindray Medical's bidding amount in June 2025 was 623 million yuan, up 15% year-on-year, with a total of 4.258 billion yuan for the first half of 2025, reflecting a 64% increase [16][18] - United Imaging's June 2025 bidding amount was 769 million yuan, a 35% year-on-year increase, totaling 4.841 billion yuan for the first half of 2025, up 53% [13][14] - Aohua Endoscopy's June 2025 bidding amount was 27 million yuan, down 46% year-on-year, with a total of 235 million yuan for the first half of 2025, up 57% [19][20] - Kaili Medical's June 2025 bidding amount was 102 million yuan, a 73% year-on-year increase, totaling 642 million yuan for the first half of 2025, up 115% [22][23] - Shanwaishan's June 2025 bidding amount was 30 million yuan, a 222% year-on-year increase, totaling 186 million yuan for the first half of 2025, up 211% [25][26] - Wandong Medical's June 2025 bidding amount was 222 million yuan, a 416% year-on-year increase, totaling 728 million yuan for the first half of 2025, up 107% [28][29] Imported Brands - Philips' June 2025 bidding amount was 658 million yuan, down 4% year-on-year, with a total of 4.570 billion yuan for the first half of 2025, up 61% [31][32] - Siemens' June 2025 bidding amount was 978 million yuan, a 48% year-on-year increase, totaling 6.074 billion yuan for the first half of 2025, up 60% [34][35] - GE's June 2025 bidding amount was 1.447 billion yuan, a 49% year-on-year increase, totaling 6.736 billion yuan for the first half of 2025, up 56% [37][38]

查看完整报告 特别申明： 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 点击注册小程序 25Q1公司收入1.24亿元，同比下降26.92%，实现归母净利润-2879.15万元，同比由盈转亏；实现扣非归母 净利润-3100.11万元。我们认为公司收入同比下滑主要系行业表现影响，医疗设备招采复苏偏弱，公司或 积极主动调整渠道库存水平，期待行业招采复苏，公司业绩逐步回暖。此外，2024年以来公司进一步布局 海外营销网络，海外多个国家的产品准入以及市场推广进展顺利，全方位提高了品牌影响力，24年海外业 务快速增长。 新产品持续推出，市场竞争力不断增强 2024年10月，公司推出AQ-150 Series 4K超高清内镜系统和AQ-120 Series内镜系统，AQ-150 Series内镜系 统通过搭载10.1英寸超大可触控液晶屏 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Views - The pharmaceutical sector underperformed the overall market this week, with the healthcare services sector leading the gains. The overall A-share market rose by 1.50%, while the biopharmaceutical sector increased by 1.82%, outperforming the market [1][33] - Merck announced a $10 billion acquisition of Verona Pharma to obtain the COPD drug Ohtuvayre, which is expected to be a significant product in the respiratory disease treatment market [2][10] - WuXi AppTec is projected to achieve a 102% increase in net profit for the first half of 2025, with revenues expected to reach 20.799 billion yuan, reflecting a growth of 20.64% [3] Summary by Sections Market Performance - The biopharmaceutical sector's price-to-earnings ratio (TTM) stands at 35.79x, which is at the 77.7 percentile of its historical valuation over the past five years [1][38] - The overall A-share market and various sub-sectors showed positive performance, with healthcare services up by 6.46% [1][33] Key Company Updates - Merck's acquisition of Verona Pharma will provide access to Ohtuvayre, a dual-target PDE3/4 inhibitor approved for COPD maintenance therapy, marking a significant advancement in treatment options [2][10] - Ohtuvayre's sales reached $71 million in Q1 2025, indicating strong market uptake and potential for expansion into other indications [22][24] Company Earnings Forecasts - WuXi AppTec's net profit for H1 2025 is expected to be 8.561 billion yuan, a 101.92% increase, driven by strong operational performance [3] - The report includes earnings forecasts for several companies, with WuXi AppTec and Mindray Medical both rated as "Outperform" [4][42] Investment Recommendations - Mindray Medical is highlighted as a leading domestic medical device company benefiting from new healthcare infrastructure and product upgrades [42] - WuXi AppTec is recognized for its comprehensive service capabilities in the new drug development outsourcing market [42] - Other recommended companies include New Industries, Huatai Medical, and Aibo Medical, each with strong market positions and growth potential [42][43][44]

Group 1: Institutional Research on Popular Companies - The top twenty companies with the highest institutional research in the past 30 days include Ice Wheel Environment, Huichuan Technology, Boshi Jie, Jun Ding Da, and Fuguang Co., Ltd. [2][9] - In the last five days, the most researched companies include Ice Wheel Environment, Yanjing Beer, Xingrong Environment, Ningbo Bank, and Superjet Co., Ltd. [2][9] - Among the top twenty companies in the past 30 days, five companies had ten or more rating agencies, namely Yanjing Beer, Huadian Electric, Huichuan Technology, Hangzhou Bank, and Kebo Da, with significant growth in net profit for 2024 compared to 2023 [2][9][11] Group 2: Major Shareholder Increase in A-Share Companies - From July 7 to July 11, 2025, six companies announced significant shareholder increases, with two companies having ten or more rating agencies: Ruipu Biological and Hisense Home Appliances [3][12] - From January 1 to July 11, 2025, a total of 237 companies announced significant shareholder increases, with 64 companies having ten or more rating agencies. Among these, 19 companies had an average proposed increase amount exceeding 1% of the latest market value [3][14] Group 3: A-Share Company Buyback Situation - From July 7 to July 11, 2025, 93 companies announced buyback progress, with 23 companies having ten or more rating agencies. Companies with a proposed buyback amount exceeding 1% of the market value include Aohua Endoscopy, Shantui Co., Ltd., Wanrun Co., Ltd., and AVIC Heavy Machinery [3][16] - From January 1 to July 11, 2025, a total of 1,117 companies announced buyback progress, with 259 companies having ten or more rating agencies. Among these, 93 companies had a proposed buyback amount exceeding 1% of the market value [3][17] Group 4: Institutional Fund Flow - From July 7 to July 11, 2025, sectors such as electric power equipment, real estate, non-bank financials, steel, computer, building materials, beauty care, light industry manufacturing, retail, non-ferrous metals, and comprehensive industries received net inflows of institutional funds [21][23] - In the past 30 days, from June 11 to July 11, 2025, sectors such as real estate, non-bank financials, steel, building materials, light industry manufacturing, and food and beverage also received net inflows of institutional funds [21][23] Group 5: Investment Recommendations - For institutional research, it is recommended to pay attention to Yanjing Beer, Huadian Electric, Hangzhou Bank, and Kebo Da, which have high research intensity and significant growth in net profit for 2024 compared to 2023 [26] - For major shareholder increases, it is suggested to focus on New Energy, Tunnel Co., Ltd., Sailun Tire, and Wanrun Co., Ltd., which have significant proposed increase amounts relative to their market values [26] - For company buybacks, attention is drawn to companies with significant buyback amounts and those in the board proposal stage, including Changhong Meiling, Liugong, Shantui Co., Ltd., and others [26]

Group 1: Trade Tariffs and Economic Impact - President Trump announced new tariffs on eight countries, with Brazil facing a 50% tariff, while Libya, Iraq, Algeria, and Sri Lanka will see a 30% tariff. Brunei and Moldova will have a 25% tariff, and the Philippines will face a 20% tariff, effective from August 1 [1] - Brazilian President Lula responded, stating that the claim of a trade deficit with the U.S. is incorrect and that any unilateral tariff increases will be met with responses under Brazil's economic reciprocity law [1] Group 2: U.S. Federal Reserve and Inflation - The Federal Reserve's meeting minutes indicated that most officials believe tariffs may continue to drive inflation higher, while a minority are open to considering interest rate cuts in the next meeting [2] Group 3: Stock Market Performance - Major U.S. stock indices showed positive performance, with the Dow Jones up 0.49%, Nasdaq up 0.94%, and S&P 500 up 0.61%. Notable tech stocks like Nvidia and Meta saw increases of 1.8% and 1.68%, respectively [3][4] - Chinese concept stocks mostly declined, with the Nasdaq Golden Dragon China Index down 1.11%. Alibaba fell by 3.85%, while Tiger Brokers rose by 3.34% [3] Group 4: Global Asset Prices - Bitcoin reached a record price of $112,000, marking a nearly 20% increase this year. WTI crude oil futures for August rose approximately 0.03% to $68.35 per barrel [4] - The U.S. dollar index showed a slight increase of 0.04%, while gold prices rose by 0.52% to $3,319.34 [5] Group 5: Corporate Developments - OpenAI is set to launch an AI browser that integrates chat features and AI agents, potentially impacting Google's advertising ecosystem and web traffic [6] - Shanghai Zhiyuan Robotics announced no significant changes to its main business in the next 12 months, nor any major asset restructuring plans [10] Group 6: Market Trends and Regulatory Actions - The Chinese government is focusing on fair competition in the market, with the State Administration for Market Regulation holding discussions with various companies to promote high-quality development in the private sector [15] - Reports indicate that silicon wafer manufacturers have raised prices by 8% to 11.7%, reflecting a broader trend of increasing costs in the semiconductor industry [16]

Summary of Key Points Core Viewpoint - Shanghai Aohua Endoscopy Co., Ltd. has announced a share repurchase plan aimed at utilizing the repurchased shares for employee stock ownership plans or equity incentives, with a total repurchase amount expected to be between RMB 100 million and RMB 200 million [1][3]. Repurchase Plan Details - The repurchase plan was first disclosed on January 6, 2025, with an implementation period from January 3, 2025, to January 2, 2026 [1]. - The maximum repurchase price is set at RMB 45.00 per share [1]. - The total number of shares repurchased is 2,499,471, accounting for 1.86% of the total share capital [3]. Implementation Status - As of the announcement date, the company has completed the share repurchase as per the disclosed plan, with a total expenditure of RMB 100,004,825.58 [3]. - The repurchase was conducted through the Shanghai Stock Exchange trading system using self-owned funds and a special loan from CITIC Bank [3]. Shareholder Transactions - During the repurchase period, there were no transactions involving the company's directors, supervisors, senior management, or controlling shareholders, except for specific increases in shareholdings by certain executives [4][5]. Share Capital Changes - Before the repurchase, the total share capital was 134,587,250 shares, which increased to 134,665,250 shares post-repurchase [6]. - The repurchased shares will be used for employee stock ownership plans or equity incentives, and any unutilized shares within three years will be canceled [6].

证券代码：688212 证券简称：澳华内镜 公告编号：2025-054 上海澳华内镜股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 重要内容提示： | | | | --- | --- | --- | | 回购方案首次披露日 | 2025/1/6 | | | 回购方案实施期限 | 2025 年 1 月 3 日~2026 年 1 月 2 | 日 | | 预计回购金额 | 10,000万元~20,000万元 | | | 回购价格上限 | 45.00元/股 | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | □用于转换公司可转债 | | | | □为维护公司价值及股东权益 | | | 实际回购股数 | 249.95万股 | | | 实际回购股数占总股本比例 | 1.86% | | | 实际回购金额 | 10,000.48万元 | | | 实际回购价格区间 | 36.98元/股~44.90元/股 | | 一、 回购审批情况和回购方案内容 上海澳华 ...